About E3 ubiquitin-protein ligase RNF130
E3 ubiquitin-protein ligase RNF130 (RNF130) is a protein
from Homo sapiens identified by UniProt accession
Q86XS8, 419 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RNF130 |
| UniProt accession | Q86XS8 |
| Gene | RNF130 |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (52)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- systolic blood pressure · score 0.36
- viral load · score 0.31
- insomnia measurement · score 0.15
- cortical thickness · score 0.15
- leukocyte count · score 0.14
- brain measurement · score 0.11
- adolescent idiopathic scoliosis · score 0.11
- neutrophil percentage of leukocytes · score 0.07
- aspartate aminotransferase measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86XS8-F1 | alphafold | PREDICTED | 73.99 | — |
Amino-acid sequence (419 residues)
MSCAGRAGPA RLAALALLTC SLWPARADNA SQEYYTALIN VTVQEPGRGA PLTFRIDRGR YGLDSPKAEV RGQVLAPLPL HGVADHLGCD PQTRFFVPPN IKQWIALLQR GNCTFKEKIS RAAFHNAVAV VIYNNKSKEE PVTMTHPGTG DIIAVMITEL RGKDILSYLE KNISVQMTIA VGTRMPPKNF SRGSLVFVSI SFIVLMIISS AWLIFYFIQK IRYTNARDRN QRRLGDAAKK AISKLTTRTV KKGDKETDPD FDHCAVCIES YKQNDVVRIL PCKHVFHKSC VDPWLSEHCT CPMCKLNILK ALGIVPNLPC TDNVAFDMER LTRTQAVNRR SALGDLAGDN SLGLEPLRTS GISPLPQDGE LTPRTGEINI AVTKEWFIIA SFGLLSALTL CYMIIRATAS LNANEVEWF
Explore E3 ubiquitin-protein ligase RNF130 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets